Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small …
Abstract Background: Anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) represents a rare subset of lung cancer, with specific presentation, and multiple treatment …
First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced ...
Jul 1, 2025 · Highlights • This research examines the cost-effectiveness of alectinib, brigatinib, and lorlatinib as first-line therapies for advanced anaplastic lymphoma kinase-positive non-small cell lung …
We aimed to investigate the cost efectiveness of lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), used first-line in Sweden to treat patients with ALK …
Cost-effectiveness of first-line versus second-line use of brigatinib ...
Feb 15, 2024 · Using brigatinib as first-line treatment followed by lorlatinib for ALK-positive NSCLC may not be cost-effective given current pricing from the perspective of a United States payer. Delaying …
Cost-effectiveness of ensartinib for patients with anaplastic lymphoma ...
Survival data were obtained from published eXalt3 clinical trials of ensartinib verses crizotinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Parametric models …
Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated ...
May 28, 2021 · Introduction: Recently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement …
Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated ...
Recently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement over crizotinib for advanced …
Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in ...
Abstract Background: Crizotinib, ceritinib, and alectinib improved survival in patients with anaplastic lymphoma kinase (ALK) arrangement non-small-cell lung cancer (NSCLC); however, the long-term …
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult ...
We aimed to investigate the cost effectiveness of lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), used first-line in Sweden to treat patients with ALK …
Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung ...
Aug 1, 2025 · In non-small cell lung cancer (NSCLC), chromosomal rearrangements involving the ALK gene loci on chromosome 2 are found in approximately 3 to 5 percent of NSCLC tumors [1,2].
We aimed to investigate the cost efectiveness of lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), used first-line in Sweden to treat patients with ...
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a …
Abstract Background Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK -rearranged non-small-cell …
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic ...
Jun 3, 2023 · Background The anaplastic lymphoma kinase (ALK) inhibitor treatment landscape is rapidly evolving, providing patients with ALK-positive (+) non-small cell lung cancer (NSCLC) with …
Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients ...
Sep 7, 2023 · Abstract Purpose The objective of the present study was to evaluate the efficiency of lorlatinib compared to alectinib and brigatinib for the treatment of adult patients with anaplastic …